Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

~ Lantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells. ~ RADR®’s AI and ML drug development modules have the potential to assist in advancing ADC drug candidates from the discovery phase to first-in-human clinical trials in approximately 2 years or less. ~ Lantern anticipates this expansion will significantly add to RADR®’s 25+ billion oncology focused data points and library of over 200+ algorithms. ~ The global ADC market is over $4.0 billion and is projected to reach $14.0 billion by 2027.